For Healthcare Professionals

Hemophilia is a disorder, mostly inherited (genetic), limiting the body’s ability develop blood clots; the natural defense mechanism against bleeding. People with the condition experience longer periods than normal for bleeding to stop as well as easier bruising and a higher risk of bleeding inside the joints or the brain. These effects greatly reduce the individual’s quality of life and include the risk of long-term headaches, seizures or decreased levels of consciousness.

The two main types of hemophilia are; Type A usually caused by insufficient blood clotting factor VIII and Type B, which is caused by reduced clotting factor IX. These two types are both linked to the X chromosome. Females are rarely affected as they carry two X chromosomes, whereas males only have one.

Treatment of hemophilia involves replacing the missing blood clotting factors – Factor VIII for hemophilia A and IX for hemophilia B. Treatment may be linked to bleeding events or, as a preventive measure for the individual’s lifetime. SG Biotech supplies a range of treatments targeted at Hemophilia A, which have been proven to be effective and convenient to use. The company serves the Russian market alone and JSC SG Biotech, Moscow is the Marketing Authorization Holder for these products in the Russia.